Last Wednesday, July 27th, Bristol Meyer Squibb’s CEO Giovanni Caforio signaled that the company has the resources to grow its holdings and it intends to do so. The company’s sales this Q2 were more than double the same period last year, giving the company more than enough funds to build off recent acquisitions.
According to Nicole Defeudis, “Reblozyl led those sales last quarter, raking in $172 million. However, the drug suffered a major setback last month when BMS pulled the plug on a program for anemia in adults with non-transfusion dependent (NTD) beta-thalassemia. At the time, the company said it withdrew an sBLA because it “could not appropriately address” the FDA’s questions about the drug’s benefit-risk profile.”
To read more, click here.
(Source: Endpoints, July 27th, 2022)
